Now I have sufficient calibration to assess the paper. Let me compile the final review.

---

## Summary

This paper identifies that 3D molecular data distributions exhibit a "dense-concentrated structure" (DC-structure) — many narrow, densely packed probability peaks separated by near-zero-density regions — which makes standard diffusion reverse inference fragile: small errors at intermediate timesteps cause overshoot into invalid regions, from which recovery is impossible. The authors formalize this via Definition 3.1 and propose DIST, a model-agnostic plug-in that, at an intermediate timestep, evaluates candidate batches via a pilot reverse pass, filters out batches with poor pilot scores, and continues inference only on retained batches. Experiments across three backbone architectures (EDM, GeoLDM, RADM) and two datasets (QM9, GEOM-Drugs) show consistent improvements in stability and validity while approximately halving the number of reverse steps.

## Strengths

- **Clear problem identification with concrete formalization.** The DC-structure (Definition 3.1) provides a useful conceptual handle for understanding why molecular diffusion is more fragile than image diffusion. The overshoot argument (Eqs. 6–7) gives an intuitive mechanistic explanation that connects the narrow-peak property to reverse-process failure modes. Table 1 empirically demonstrates that degradation accumulates with starting timestep, corroborating the analysis.

- **Consistent, architecture-agnostic empirical gains.** Table 2 shows DIST improves every backbone on every metric across both datasets — including GNN-based equivariant models (EDM), VAE-latent models (GeoLDM), and Transformer-based non-equivariant models (RADM). The improvements are substantial: e.g., EDM molecule stability rises from 82.0% to 89.9% on QM9, and from 81.3% to 82.2% atom stability on GEOM-Drugs. The use of official pretrained weights without hyperparameter changes strengthens the plug-in claim.

- **Efficiency improvement alongside quality.** Table 3 shows DIST reduces average timesteps to roughly 400–640 (vs. 1000 for baselines). Table 4 confirms that even with a small pilot budget (30 pilots, 428.3 steps), DIST outperforms the baseline EDM (82.0% → 89.5% mol stability), demonstrating a favorable quality–cost tradeoff.

- **Reasonable ablation.** The pilot-subset-size ablation (Table 4) confirms that steering quality improves monotonically with more pilots, validating the core mechanism and providing a tunable cost–quality knob.

## Weaknesses

### Fatal

None.

### Major

None.

### Minor

- **The specific pilot score function is not stated in the main text.** The paper lists candidate scores (round-trip residual, self-consistency, ensemble variance, chemistry-based penalty) but the concrete choice used in experiments is deferred to Appendix F. Since the pilot score is the core filtering mechanism, the main text would benefit from at least naming which variant was selected and briefly justifying it. This does not invalidate the results, but it makes the main paper less self-contained than ideal.

- **The theoretical contributions are primarily heuristic framing rather than rigorous guarantees.** Definition 3.1 formalizes the DC-structure but the parameters σ₊, Δ are never estimated from data. The overshoot derivation (Eqs. 6–7) assumes Gaussian peaks and a simplified score magnitude. Corollary 3.1 asserts the existence of a contraction coefficient κ without characterizing it — it is essentially a restatement that TV distance is non-expanding under a Markov kernel. Proposition 3.1 defers its explicit bound to the appendix, and its dependence on hyperparameters (τ, batch radius r) is not empirically explored in the main text. The theory successfully motivates the method but does not constitute formal verification. This is acceptable for an empirical paper but the paper should not overstate the rigor.

- **GEOM-Drugs results for DIST are reported without variability estimates.** Table 2 reports standard deviations (±) for QM9 runs but not for GEOM-Drugs, where only point estimates are shown. This makes the GEOM-Drugs comparison harder to assess for statistical significance.

- **Cost comparison does not include fast-sampling baselines.** The efficiency analysis compares DIST (reduced steps) against the standard 1000-step baseline. A comparison against baselines using fewer steps (e.g., DDIM-style fast sampling) with equal total compute budget would strengthen the efficiency claim. That said, the paper does account for pilot and discarded-batch costs in its step-count calculation, which is appropriate.

### Trivial

- The paper would benefit from naming the specific pilot score variant in the main text (e.g., in Section 3.2 or 4.1) rather than deferring it entirely to the appendix.

## Nice-to-Haves

- An equal-compute comparison where baseline models are run with fewer steps (matching DIST's total step budget including pilot/discard overhead) would more directly test whether the filtering mechanism provides a net benefit beyond spending extra computation on high-quality trajectories.
- Reporting which fraction of candidate batches are discarded at the filtering step, and what proportion of total cost goes to pilot runs versus the final reverse pass, would clarify the efficiency mechanism.
- An ablation replacing the pilot score with a random filter or a purely chemistry-based rule would help disentangle model-driven steering from external chemical knowledge.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **Harsh Critic claim: "The pilot score is unspecified… a fundamental omission… the method cannot be reproduced."** → The pilot score specification is in Appendix F, which is stripped by the parser. Per instructions, weaknesses about missing appendix content must be removed. The main-text omission is noted above as a minor weakness, not a fatal one.

- **Harsh Critic claim: "Computational cost comparisons are misleading… no comparison with a baseline that uses a comparable overall budget."** → The paper does account for pilot and discarded-batch costs in its timestep numbers (the per-sample timesteps in Tables 3–4 include amortized overhead). The critique about fast-sampling baselines is a scope-expansion request, not a flaw in the existing comparison. Demoted to minor.

- **Harsh Critic claim: "The bound's dependence on τ and the batch radius is never explored in experiments… the ablation only varies pilot subset size."** → The paper states these ablations are in Appendix H, which is stripped. Per rules, removed.

- **Harsh Critic Section-by-Section claim: "It is never explained how the pilot score s_j is concretely computed from this pilot run, nor what 'full reverse inference' means."** → "Full reverse inference" clearly means running the reverse process to completion (t → 0). The concrete computation is in Appendix F. Removed.

- **Strength Finder: "A formal and quantitative characterization of the distributional challenge."** → Partially tempered — the characterization is formal but qualitative (parameters are never estimated). Retained in modified form above.

- **Strength Finder: "Theoretical guarantee for the correcting mechanism (Proposition 3.1)."** → The bound's explicit form is deferred to the appendix. The proposition provides qualitative support rather than a quantitative guarantee. Retained with caveat.

## Novel Insights

The paper's most genuinely novel observation is the identification and formalization of the DC-structure as a specific property of molecular distributions that explains why diffusion models are more fragile for molecules than for images. While prior work has noted that molecular generation is challenging, the paper provides a concrete mechanism (overshoot due to narrow peaks, Eq. 7) and empirically demonstrates through Table 1 that degradation accumulates with reverse-process length — offering a clear causal narrative rather than a vague observation. The insight that correcting intermediate distributions (rather than improving architectures or training objectives) is sufficient to substantially improve final generation quality, and that this can be done in a model-agnostic plug-in fashion, is a practically valuable contribution to the molecular generation literature.

## Suggestions

- Move the specific pilot score choice from Appendix F into the main text (even one sentence in Section 4.1 would suffice) so the paper is self-contained on its core mechanism.
- Add variability estimates (standard deviations over multiple runs) for GEOM-Drugs results to match the QM9 reporting standard.
- Consider an equal-compute comparison against fast-sampled baselines (e.g., DDIM with 500 steps) to more rigorously validate the efficiency claim.

## Score and Decision

**Calibration anchor comparison:**

| Anchor | Avg Score | Round | Comparison |
|--------|-----------|-------|------------|
| DynamicsDiffusion (kKXIYUi8ff) | 3.00 | 1 | Much weaker — limited scope, unclear results |
| MoreRed (rwmWd2rjP1) | 4.75 | 1 | Narrower contribution, less comprehensive evaluation |
| VFDiff (5YLsnsjgeC) | 6.00 | 2 | Similar domain but less consistent improvements |
| TFG-Flow (GK5ni7tIHp) | 6.25 | 2 | Interesting idea but reviewers found conceptual gaps |
| Megalodon (9UoBuhVNh6) | 6.33 | 1 | Strong results but limited to one dataset, novelty concerns |
| Lift Your Molecules (uNomADvF3s) | 6.50 | 1 | Novel idea but core hypothesis not fully validated |
| DrugFlow (g3VCIM94ke) | 6.67 | 2 | Multiple contributions but statistical concerns in evaluation |
| UniGEM (Lb91pXwZMR) | 6.67 | 2 | Unified approach but some experimental gaps |
| Stiefel Flow Matching (84WmbzikPP) | 7.00 | 2 | Mathematically novel but limited baselines, validity issues |
| GeoBFN (NSVtmmzeRB) | 8.00 | 1 | New generative paradigm, SOTA, stronger theoretical grounding |
| ShEPhERD (KSLkFYHlYg) | 8.00 | 1 | Novel problem formulation, strong results |

**Bracket (Round 1):** 6.0–8.0. The paper is clearly above the weak anchors (3.00–4.75) and below the top-tier anchors (8.00).

**Narrowing (Round 2):** The paper sits between DrugFlow/UniGEM (6.67) and Stiefel Flow Matching (7.00). DIST has broader empirical validation than Stiefel (3 backbones, 2 datasets vs. essentially 1 baseline), and its results are more consistent than DrugFlow's. However, DIST lacks the mathematical novelty of Stiefel's manifold embedding. Overall, DIST is comparable to Stiefel Flow Matching in overall contribution quality — slightly stronger empirically, slightly less novel theoretically. The theoretical contributions are primarily heuristic framing, which caps the score below the 8.0 tier where genuinely new generative paradigms or formulations are introduced.

**Final score:** 7.0 — a solid, well-executed contribution with clear practical value, consistent empirical evidence, and a useful conceptual framework, held back from the top tier by theoretical contributions that are more motivational than rigorous.

MY FINAL SCORE: <score>7.0</score>
MY FINAL DECISION: <decision>Accept</decision>